Symptomatic hyperammonemia secondary to recombinant Erwinia asparaginase
Pediatric Blood & Cancer · 2023-05 · 70 (5)
DOI: 10.1002/pbc.30208 ↗Kurz gefasst
Leserbrief in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 12.01.2023. Verfasst von Catherine E Martin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy - Ambulatory Service, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Hyperammonemia, Antineoplastic Agents, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Erwinia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy - Ambulatory Service, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Pediatric and Adolescent Medicine, Division of Pediatric Hematology/Oncology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Catherine E Martin, Mira A Kohorst, Paul J Galardy, Alexis K Kuhn
Zitieren
APA
Martin, C. E., Kohorst, M. A., Ferdjallah, A., Kalmes, J. L., Johnson, H. M., Galardy, P. J., Khan, S. P., & Kuhn, A. K. (2023). Symptomatic hyperammonemia secondary to recombinant Erwinia asparaginase. Pediatric Blood & Cancer, 70(5). https://doi.org/10.1002/pbc.30208
Vancouver
Martin CE, Kohorst MA, Ferdjallah A, Kalmes JL, Johnson HM, Galardy PJ, et al. Symptomatic hyperammonemia secondary to recombinant Erwinia asparaginase. Pediatric Blood & Cancer. 2023;70(5). doi:10.1002/pbc.30208
BibTeX
@article{Martin2023,
author = {Martin, Catherine E and Kohorst, Mira A and Ferdjallah, Asmaa and Kalmes, Jessica L and Johnson, Heather M and Galardy, Paul J and Khan, Shakila P and Kuhn, Alexis K},
title = {Symptomatic hyperammonemia secondary to recombinant Erwinia asparaginase},
journal = {Pediatric Blood & Cancer},
year = {2023},
volume = {70},
number = {5},
doi = {10.1002/pbc.30208}
}
EUVIMED